Respiratory Tract Neoplasms  >>  Xcytrin (motexafin gadolinum)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xcytrin (motexafin gadolinum) / AbbVie
NCT00129844: Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Completed
2
108
US, Canada
Motexafin Gadolinium
Pharmacyclics LLC.
Adenocarcinoma, Non-Small-Cell Lung Carcinoma, Lung Neoplasms
06/07
12/07
NCT00365183: Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Terminated
2
74
US
Motexafin gadolinium and pemetrexed, MGd and Alimta®
Pharmacyclics LLC.
Non-Small Cell Lung Carcinoma
01/08
06/08
NCT00373204: Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Terminated
2
50
US, Canada, RoW
Motexafin Gadolinium, MGd and Docetaxtel
Pharmacyclics LLC.
Lung Cancer
02/08
05/08

Download Options